Hepion's NASH drug meets main goal in mid-stage trial (updated)
22/05/2023 12:20
(Adds shares in paragraph 1, details in paragraphs 2 & 3)
May 22 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O
said on Monday its treatment met the main goal of improving
liver function in patients with a type of fatty liver disease in
a mid-stage study trial, sending its shares 45% higher in
premarket trading.
The drug, rencofilstat, was also found to be safe in the
61-patient trial, with the 225 mg dose showing the greatest
benefit to liver function and multiple biomarkers associated
with NASH (non-alcoholic steatohepatitis), the company said.
Hepion was conducting trials on three doses, with the 225 mg
dose being the highest.
(Reporting by Leroy Leo in Bengaluru; Editing by Rashmi Aich)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement